Search research articles
Contact Us
Filters
Showing results (61-70 of 87) with videos related to
Page
of 9
Sort By:
Onkologie
|
December 1, 1990
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group
D Peest, H Deicher, R Coldewey, et al.
Experimental Hematology
|
December 9, 1998
Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia
M Gramatzki, W D Ludwig, R Burger, et al.
Cancer Research
|
February 15, 1997
Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer
B Stockmeyer, T Valerius, R Repp, et al.
British Journal of Haematology
|
February 1, 1994
The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7
J Greil, M Gramatzki, R Burger, et al.
Cancer Research
|
December 1, 1995
67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma
W S Becker, T M Behr, F Cumme, et al.
British Journal of Cancer
|
November 17, 2001
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial
J Atzpodien, H Kirchner, H J Illiger, et al.
The Journal of Urology
|
January 17, 2002
Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?
H Stadick, B Stockmeyer, R Kühn, et al.
Cytometry. Part B, Clinical Cytometry
|
April 30, 2003
Immunophenotyping is an independent factor for risk stratification in AML
R Repp, U Schaekel, G Helm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies
T M Behr, B Wörmann, M Gramatzki, et al.
Annals of Hematology
|
October 24, 2000
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group
M Feuring-Buske, M Kneba, M Unterhalt, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 87) with videos related to
Sort By:
Page
of 9
Onkologie
|
December 1, 1990
Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group
D Peest, H Deicher, R Coldewey, et al.
Experimental Hematology
|
December 9, 1998
Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia
M Gramatzki, W D Ludwig, R Burger, et al.
Cancer Research
|
February 15, 1997
Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer
B Stockmeyer, T Valerius, R Repp, et al.
British Journal of Haematology
|
February 1, 1994
The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7
J Greil, M Gramatzki, R Burger, et al.
Cancer Research
|
December 1, 1995
67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma
W S Becker, T M Behr, F Cumme, et al.
British Journal of Cancer
|
November 17, 2001
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial
J Atzpodien, H Kirchner, H J Illiger, et al.
The Journal of Urology
|
January 17, 2002
Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?
H Stadick, B Stockmeyer, R Kühn, et al.
Cytometry. Part B, Clinical Cytometry
|
April 30, 2003
Immunophenotyping is an independent factor for risk stratification in AML
R Repp, U Schaekel, G Helm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies
T M Behr, B Wörmann, M Gramatzki, et al.
Annals of Hematology
|
October 24, 2000
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group
M Feuring-Buske, M Kneba, M Unterhalt, et al.
Page
of 9